Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.10.155PMID 15365068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• Systemic therapy for renal cell carcinoma.

  2000cited by this paper
• The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death.

  1998cited by this paper
• The proteasome.

  1997cited by this paper
• New insights into the mechanisms and importance of the proteasome in intracellular protein degradation.

  1997cited by this paper
• The proteasome: a macromolecular assembly designed to confine proteolysis to a nanocompartment.

  1997cited by this paper
• Renal-cell carcinoma.

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• The ubiquitin system for protein degradation.

  1992cited by this paper
• The multicatalytic proteinase complex, a major extralysosomal proteolytic system.

  1990cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Spontaneous regression of metastatic renal cell carcinoma.

  1982cited by this paper

• The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells

  2025cites this paper
• Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma

  2025cites this paper
• Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma

  2024cites this paper
• Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

  2024cites this paper
• The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer

  2024cites this paper
• Inflammatory Networks in Renal Cell Carcinoma

  2023cites this paper
• An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases

  2023cites this paper
• Surgical and oncological management of renal medullary carcinoma in a young patient: a case report

  2023cites this paper
• PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

  2023cites this paper
• Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma

  2022cites this paper
• Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

  2022cites this paper
• Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells

  2021cites this paper
• Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib

  2021cites this paper
• Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells

  2021cites this paper
• Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.

  2021cites this paper
• The Proteasome Inhibitor Bortezomib Induces Tongue, Pharynx and Salivary Gland Cancer Cells Death in Vitro and Delays Tumor Growth of Salivary Gland Cancer Cells Transplanted in Mice

  2021cites this paper
• Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

  2021cites this paper
• Fatty Acids Metabolism: The Bridge Between Ferroptosis and Ionizing Radiation

  2021cites this paper
• Renal medullary carcinoma

  2020cites this paper
• From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.

  2020cites this paper
• Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.

  2019cites this paper
• Management of Non-Clear Cell Renal Cell Carcinoma

  2019cites this paper
• Toward a genome-based treatment landscape for renal cell carcinoma.

  2019cites this paper
• Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)‐protease inhibitors lopinavir or nelfinavir

  2018cites this paper
• Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review

  2018cites this paper
• Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma

  2018cites this paper
• Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.

  2018cites this paper
• Renal Medullary Carcinoma; A Rare Entity

  2017cites this paper
• P‐Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors

  2017cites this paper
• Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.

  2017cites this paper
• Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases

  2017cites this paper
• The role of precision medicine for the treatment of metastatic renal cell carcinoma

  2016cites this paper
• Control of Hedgehog Signalling by the Cilia-Regulated Proteasome

  2016cites this paper
• BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition.

  2016cites this paper
• Renal Medullary Carcinoma

  2016cites this paper
• The prospect of precision therapy for renal cell carcinoma.

  2016cites this paper
• Treating renal cell carcinoma in young adults: challenges and solutions

  2016cites this paper
• Protéine-kinases et cancer du rein : Découverte et validation d’une nouvelle combinaison d’inhibiteurs ciblant les protéine-kinases ATM et CK2

  2016cites this paper
• The cilia-regulated proteasome and its role in the development of ciliopathies and cancer

  2016cites this paper
• Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.

  2015cites this paper
• Title Systems biology-defined NF-κ B regulons , interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p 53 status

  2015cites this paper
• Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

  2015influential citation
• HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.

  2015cites this paper
• Vaccines in RCC: Clinical and Biological Relevance

  2015cites this paper
• HIF-2α dependent lipid storage promotes endoplasmic reticulum homeostasis in clear cell renal cell carcinoma

  2015cites this paper
• Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

  2015cites this paper
• Metabolic alterations in renal cell carcinoma.

  2015cites this paper
• The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies

  2015cites this paper
• Cystic Presentation of a Renal Medullary Carcinoma in a Young Woman

  2015cites this paper
• Renal medullary carcinoma: a case report and review of the literature

  2015cites this paper
• Renal Medullary Carcinoma in a White Adolescent With Sickle Cell Trait

  2014cites this paper
• Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

  2014cites this paper
• Renal Medullary Carcinoma

  2014cites this paper
• Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab

  2014cites this paper
• Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.

  2014cites this paper
• Targeting the Proteasome Pathway for the Treatment of Solid Tumors

  2014cites this paper
• Oxidative Stress and the Proteasome: Mechanisms and Therapeutic Relevance

  2014cites this paper
• Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

  2014cites this paper
• Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.

  2014cites this paper
• Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

  2014cites this paper
• Renal medullary carcinoma: a case report and brief review of the literature.

  2014cites this paper
• Proteasome inhibitor patents (2010 – present)

  2014cites this paper
• A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

  2013cites this paper
• Deregulation of the COP9 signalosome-cullin-RING ubiquitin-ligase pathway: mechanisms and roles in urological cancers.

  2013cites this paper
• Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

  2013cites this paper
• Potential biofluid markers and treatment targets for renal cell carcinoma

  2013cites this paper
• BORTEZOMIB : PROTEASOME INHIBITION AS AN EFFECTIVE ANTICANCER THERAPY

  2013cites this paper
• Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

  2012cites this paper
• Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.

  2012cites this paper
• Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis

  2012cites this paper
• Targeting the ubiquitin+proteasome system in solid tumors.

  2012cites this paper
• Immune Mechanism of the Antitumor Effects Generated by Bortezomib

  2012cites this paper
• Targeting the Ubiquitin Proteasome System in Solid Tumors

  2012cites this paper
• Identifikation des HIV-Proteaseinhibitors Ritonavir als Medikament mit potentieller Wirksamkeit in der Therapie der Akuten Myeloischen Leukämie in Kombination mit Proteasominhibitoren

  2012cites this paper
• Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

  2012cites this paper
• Targeted Anti-Cancer Therapies for Renal Cancer

  2012cites this paper
• New therapeutic agents in uveal melanoma.

  2012cites this paper
• Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein

  2012cites this paper
• Therapy for non-clear cell histologies in renal cancer.

  2011cites this paper
• Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile

  2011cites this paper
• Clinicopathologic significances of nuclear expression of nuclear factor-κB transcription factors in retinoblastoma

  2011cites this paper
• Caveolin 1 protein expression in renal cell carcinoma predicts survival

  2011cites this paper
• Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease

  2011cites this paper
• Advances in the understanding of mechanisms and therapeutic use of bortezomib.

  2011cites this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cites this paper
• Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

  2011cites this paper
• Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

  2011cites this paper
• Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer.

  2011cites this paper
• Qualitative und quantitative Analyse und Vergleich von Tumorantigenen und HLA Klasse I-Liganden in Primärtumoren und Metastasen des Nierenzellkarzinoms

  2011cites this paper
• Proteasome inhibitor treatment in alcoholic liver disease.

  2011cites this paper
• A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

  2011cites this paper
• Immunological therapy in urological malignancy: Novel combination strategies

  2011cites this paper
• Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I

  2011cites this paper
• Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.

  2010cites this paper
• Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients

  2010cites this paper
• The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

  2010cites this paper
• Reduction of transforming growth factor‐β type II receptor is caused by the enhanced ubiquitin‐dependent degradation in human renal cell carcinoma

  2010cites this paper
• Bortezomib: a new pro-apoptotic agent in cancer treatment.

  2010cites this paper
• Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

  2010cites this paper